|
Op-Ed: Mark Cuban shows how the free
market helps patients
By Sally Pipes | Pacific Research Institute
Billionaire investor Mark
Cuban is known for his razzle-dazzle. Not only has he backed a long
string of tech, media, and cryptocurrency companies, he also owns the
Dallas Mavericks basketball team and is a TV star on "Shark Tank." |
|
 Getting into discount drugs might not have seemed like an obvious next move for
Mr. Cuban. But that's exactly what he did last month, when he launched Mark
Cuban Cost Plus Drugs.
The company's goal is to offer safe and affordable medicines at transparent
prices. It's a noble cause, given that one in four Americans has trouble
affording their prescriptions.
Cuban has clearly observed that the inflated prices consumers
pay for generic medicines are ripe for disruption. Congress should take note of
his strategy.
Cost Plus offers more than 100 generic prescription medicines, many at
eye-popping discounts.
Take fluoxetine, the generic equivalent of Prozac, a treatment for depression. A
30-day supply of the generic normally retails for $21.92. You can get the same
thing from Cost Plus for $3.90.
A 30-count supply of the cancer drug imatinib sells for $17.10, compared to a
whopping $2,502.50 at other drug stores.
The list goes on. Cost Plus requires consumers to pay for medications out of
pocket and doesn't process insurance claims. But its drugs cost less than most
patients would pay elsewhere even with insurance.
How are these discounts possible? Cuban isn't selling products at a loss. His
company is just bypassing drug-industry middlemen and their exorbitant markups.
[to top of second column] |
A new study by the Berkeley Research Group shows
how steep those markups are. More than half of gross drug
expenditures – the total spent on prescription medicine at the
consumer end, either by patients or their health plans – goes to
middlemen.
Those middlemen include insurers, hospitals,
pharmacies, the government, and pharmacy benefit managers – murky
go-betweens who use their buying power to extract discounts from
drug makers while seldom passing the savings to consumers.
The study found that the share of drug spending going to middlemen
is rising. From 2013 to 2020, their portion of the intake from drug
spending rose from 37% to 51%.
In other words, middlemen have been taking in more
and more – with zero benefit to consumers.
Cuban deserves credit for creating a business model that not only
saves consumers money on their medicine but shows the extent to
which middlemen have been ripping off patients.
For years now, Congress has debated how to rein in the predatory
practices of pharmacy benefit managers, with proposed bills that
would require greater transparency. But the private sector is now
leading the way. Cuban's company could serve as a model and first
step for fixing the price-inflated status quo.
Sally C. Pipes is President, CEO, and Thomas W. Smith
Fellow in Health Care Policy at the Pacific Research Institute. Her
latest book is False Premise, False Promise: The Disastrous Reality
of Medicare for All (Encounter 2020). Follow her on Twitter
@sallypipes. |
